Themis Medicare Q4 FY26 Results: Revenue Rs 76.53 Crore, Net Profit Rs 23.92 Crore and Key Highlights
- May 29, 2026
- Posted by: Neeraj Pandey
- Category: News
Themis Medicare Q4 FY26 results were declared on May 28, 2026. The company reported net profit of Rs 23.92 crore for the quarter ended March 31, 2026. Revenue from operations was Rs 76.53 crore. Themis Medicare is a Pharmaceutical Formulations company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Themis Medicare Q4 FY26 Financial Highlights
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations (Rs Cr) | 76.53 | Prior Year | See BSE/NSE filing |
| Net Profit (PAT) (Rs Cr) | 23.92 | Prior Year | See BSE/NSE filing |
| Reporting Basis | Standalone / Consolidated (see BSE/NSE filing) | ||
Data sourced from company filings and public disclosures. Always verify from BSE/NSE audited filings before investment decisions.
Themis Medicare Q4 FY26 Performance Analysis
The Themis Medicare Q4 FY26 results reflect performance in the January to March 2026 quarter. Revenue was Rs 76.53 crore as per the audited filing. Net profit of Rs 23.92 crore reflects the company operational performance. Themis Medicare operates in the Pharmaceutical Formulations sector.
India macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth above 6.5%, government capex of Rs 11.21 lakh crore for FY27, and the RBI accommodative policy stance. The Pharmaceutical Formulations sector benefited from these structural tailwinds during the January to March 2026 quarter.
Key Business Factors in Q4 FY26
Revenue and Volume Performance
Revenue from operations was Rs 76.53 crore in Q4 FY26 for Themis Medicare. The Pharmaceutical Formulations sector benefited from India domestic demand recovery and infrastructure push in FY26.
Profitability and Margin Trajectory
Q4 FY26 net profit of Rs 23.92 crore demonstrates the company performance.
Sector and Macro Backdrop
India macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI accommodative policy stance. The Pharmaceutical Formulations sector benefited from these structural tailwinds during the quarter ended March 31, 2026.
FY27 Outlook
Following the Themis Medicare Q4 FY26 results, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and business strategy. India GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Themis Medicare in FY27.
Themis Medicare Stock Performance
Download the Univest iOS App or Univest Android App to track live price and daily stock recommendations.
Shares of Themis Medicare are listed on NSE and BSE. Following the Q4 FY26 results on May 28, 2026, investors should monitor post-results price action and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.
Key Risks
Revenue and Demand Risk
Any deceleration in India GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Themis Medicare products and services in the Pharmaceutical Formulations sector in FY27.
Margin and Cost Volatility
Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks. Any cost escalation without corresponding pricing power could compress profitability.
Conclusion
Themis Medicare Q4 FY26 results declared on May 28, 2026 showed net profit of Rs 23.92 crore. Investors should monitor management guidance and sector trends before making investment decisions.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE/NSE audited filings.
Frequently Asked Questions on Themis Medicare Q4 FY26 Results
What is Themis Medicare Q4 FY26 net profit?
Ans. Themis Medicare Q4 FY26 net profit was Rs 23.92 crore. Results declared May 28, 2026.
What is Themis Medicare Q4 FY26 revenue?
Ans. Themis Medicare Q4 FY26 revenue was Rs 76.53 crore.
When were Themis Medicare Q4 FY26 results declared?
Ans. Themis Medicare Q4 FY26 results were declared on May 28, 2026 at the board meeting approving audited financial statements for the quarter and year ended March 31, 2026.
What is the FY27 outlook for Themis Medicare?
Ans. Following Themis Medicare Q4 FY26 results, management guidance on revenue growth, margin improvement, and sector dynamics shapes FY27 expectations. Consult a SEBI-registered advisor before investing.
Is Themis Medicare a good stock to buy after Q4 FY26 results?
Ans. Investment decisions require assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This content is educational only. Consult a SEBI-registered financial advisor.
What sector does Themis Medicare operate in?
Ans. Themis Medicare operates in the Pharmaceutical Formulations sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 28, 2026.
